{"id":584482,"date":"2025-09-16T00:00:00","date_gmt":"2025-09-16T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0025-2025-biopharma-ischemic-stroke-current-treatment-current-treatment-physician-insights-acute-ischemic-stroke\/"},"modified":"2025-09-16T00:00:00","modified_gmt":"2025-09-16T00:00:00","slug":"cutrcg0025-2025-biopharma-ischemic-stroke-current-treatment-current-treatment-physician-insights-acute-ischemic-stroke","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0025-2025-biopharma-ischemic-stroke-current-treatment-current-treatment-physician-insights-acute-ischemic-stroke\/","title":{"rendered":"Ischemic Stroke &#8211; Current Treatment &#8211; Current Treatment: Physician Insights &#8211; Acute Ischemic Stroke (US)"},"content":{"rendered":"<p>Ischemic stroke (<abbr title=\"ischemic stroke\">IS<\/abbr>) is a leading cause of death and neurological disability worldwide. Recombinant tissue plasminogen activator formulations\u2014alteplase (Genentech\u2019s Activase, other brands) and tenecteplase (Genentech\u2019s TNKase)\u2014are the only pharmacological therapies approved for the acute treatment of <abbr title=\"ischemic stroke\">IS<\/abbr> owing to the persistent failure of investigational compounds over the past two decades. However, because of strict initiation criteria and safety risks, only a small fraction of diagnosed <abbr title=\"ischemic stroke\">IS<\/abbr> events receive pharmacotherapies. Thus, a high level of unmet clinical need remains for treatments that can prevent permanent neurological damage and restore function in post-stroke survivors living with residual impairment. This report provides data and insight on the treatment of <abbr title=\"ischemic stroke\">IS<\/abbr> in the United States, including the drivers of and obstacles to the use of key therapies.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What percentage of <abbr title=\"ischemic stroke\">IS<\/abbr> patients arrive at the hospital within key time windows for acute drug and\/or device intervention? What percentage of <abbr title=\"ischemic stroke\">IS<\/abbr> patients receive these interventions?<\/li>\n<li>How do <abbr title=\"ischemic stroke\">IS<\/abbr> patients differ with regard to functional outcomes after a stroke? Which scales are used to measure these outcomes?<\/li>\n<li>What post-stroke therapies do <abbr title=\"ischemic stroke\">IS<\/abbr> patients receive? What specialties are involved in their long-term care?<\/li>\n<li>What is the near-term outlook for the uptake of Roche \/ Genentech\u2019s TNKase in <abbr title=\"ischemic stroke\">IS<\/abbr>? What factors will influence its use?<\/li>\n<\/ul>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Primary research: <\/strong>Survey of <span>100 <\/span>U.S.-based specialists, including <span>70 <\/span>neurologists and <span>30 <\/span>neurosurgeons\/interventional radiologists<\/p>\n<p><strong>Key therapies covered:<\/strong><strong>\u00a0<\/strong>Tenecteplase (TNKase), alteplase (Activase), stroke sequelae drugs, neuroprotective agents, secondary prevention drugs, and mechanical endovascular thrombectomy devices<\/p>\n<p><strong>Key analyses<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Patient characteristics<\/li>\n<li>Patient journey<\/li>\n<li>Factors influencing disease treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<li>Rationale for changes in treatment approach<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Understand the treatment landscape for a disease and how physicians make prescribing decisions.<\/li>\n<li>Evaluate the drivers and obstacles that influence treatment selection.<\/li>\n<li>Analyze your brand\u2019s performance from the physician perspective to enhance or defend your competitive position.<\/li>\n<li>Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-584482","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-ischemic-stroke","biopharma-therapy-areas-neurology","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/584482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=584482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}